Misplaced Pages

Heather Bresch: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 19:58, 21 January 2015 editDragonflySixtyseven (talk | contribs)Autopatrolled, Administrators87,958 edits parents← Previous edit Revision as of 02:03, 22 January 2015 edit undoTanar Aerdoth (talk | contribs)22 editsm →Controversy: typoNext edit →
Line 26: Line 26:
{{main|Heather Bresch M.B.A. controversy}} {{main|Heather Bresch M.B.A. controversy}}


In In 2007, the '']'' reported that Bresch claimed to have an MBA degree from ], but that when asked, the university disputed this. The university subsequently awarded her an MBA, despite her having completed only 26 of the required 48 credits. In the ensuing controversy, WVU President ] resigned.<ref>, ''MSNBC.com'' 6 June 2008, accessed 2008-06-06</ref> In 2007, the '']'' reported that Bresch claimed to have an MBA degree from ], but that when asked, the university disputed this. The university subsequently awarded her an MBA, despite her having completed only 26 of the required 48 credits. In the ensuing controversy, WVU President ] resigned.<ref>, ''MSNBC.com'' 6 June 2008, accessed 2008-06-06</ref>


==Personal life== ==Personal life==

Revision as of 02:03, 22 January 2015

Heather Manchin Bresch
Heather Bresch testifying before the United States House Committee on Energy and Commerce in 2012.
NationalityAmerican
Alma materWest Virginia University
OccupationChief executive officer

Heather Bresch is the CEO of Mylan, Inc., a Pittsburgh-based pharmaceutical corporation.

Career

Bresch's previous roles included serving as Mylan's president, chief operating officer, head of North American operations and chief integration officer. Bresch was appointed to Mylan's Board of Directors in March 2011. She has been active in attempts to prevent brand-name pharmaceuticals from delaying the release of generic drugs and appeared before a special United States Senate committee on the issue in 2006 and again in 2009. Bresch also testified before the Food and Drug Administration in September 2010 on the issue of generic drug user fees, proposing a new user fee structure that aims to generate more funding for the FDA and provide greater assurance for pharmaceutical product safety, regardless of where in the world the product or its ingredients come from. On February 9, 2012, Bresch testified before the U.S. House of Representatives' Committee on Energy and Commerce in relation to drug supply chain integrity, drug shortages and the Generic Industry's Drug User Fee proposal (GDUFA).

Honors

Bresch was named one of Fortune's "50 Most Powerful Women In Business" in 2012 and 2013. In 2011, Bresch was named a Patriot of the Year by Esquire Magazine for her work which led to the passage of the FDA Safety and Innovation Act - legislation which will require foreign drugmakers that sell product in the U.S. to pay for regular facility inspections to support the FDA's efforts to continue ensuring drug safety for all U.S. consumers. Also in 2011, Bresch was named one of Pharmaceutical Executive's "Emerging Pharma Leaders 2011." In 2009, Bresch was named one of the top women in the global pharmaceutical industry by FiercePharma.

Controversy

Main article: Heather Bresch M.B.A. controversy

In 2007, the Pittsburgh Post-Gazette reported that Bresch claimed to have an MBA degree from West Virginia University, but that when asked, the university disputed this. The university subsequently awarded her an MBA, despite her having completed only 26 of the required 48 credits. In the ensuing controversy, WVU President Michael Garrison resigned.

Personal life

Bresch is the daughter of Joe Manchin and Gayle Conelly.

References

  1. http://investor.mylan.com/management.cfm
  2. “Robert Cindrich, Heather Bresch named to Mylan board”, Pittsburgh Business Times, 1 March 2011
  3. "Mylan Calls for End to Abusive Practices That Delay Access to Affordable Pharmaceuticals", PR Newswire, 20 July 2006, accessed 2008-04-24
  4. "Mylan testifies before Senate special committee on aging", Observer-Reporter (Washington, PA), 21 July 2006, accessed on 2008-04-24
  5. Brent Kendall, "Lawmakers, Drug Makers Spar Over Patent Settlements", Wall Street Journal, 3 June 2009
  6. http://www.fda.gov/downloads/Drugs/NewsEvents/UCM226845.pdf
  7. http://republicans.energycommerce.house.gov/Media/file/Hearings/Health/20120209/HTMG-112-HHRG-IF14-WState-HBresch-20120209.pdf
  8. http://money.cnn.com/magazines/fortune/most-powerful-women/2012/full_list/
  9. "Esquire's Americans of the Year: Patriots", Esquire Magazine, 19 November 2011, accessed 2012-01-31
  10. http://pharmexec.findpharma.com/pharmexec/Profiles/Emerging-Pharma-Leaders-2011/ArticleStandard/Article/detail/726109?contextCategoryId=48158
  11. "Heather Bresch - Top 15 Women in Pharma”, FiercePharma 12 Oct. 2009
  12. "College president to quit over degree scandal", MSNBC.com 6 June 2008, accessed 2008-06-06

Template:Persondata

Categories: